Table 1. Baseline characteristics of 1023 participants reporting angina frequency.
Characteristic | Angina Frequency |
P-value | ||
---|---|---|---|---|
Absent (N = 633 |
Monthly N = 279 |
Daily or Weekly N = 111 |
||
Age (years), mean ± SD | 68 ± 11 | 65 ± 11 | 66 ± 12 | <.001 |
Male | 534 (84%) | 221 (79%) | 85 (77%) | 0.048 |
Caucasian | 391 (62%) | 156 (56%) | 67 (60%) | 0.28 |
Smoking | 100 (16%) | 67 (24%) | 34 (31%) | <.001 |
Hypertension | 421 (67%) | 213 (76%) | 89 (80%) | 0.001 |
Myocardial Infarction | 330 (52%) | 151 (54%) | 66 (59%) | 0.28 |
Heart Failure | 89 (14%) | 63 (23%) | 27 (24%) | 0.001 |
Diabetes | 155 (24%) | 81 (29%) | 29 (26%) | 0.37 |
Revascularization | 382 (60%) | 155 (56%) | 65 (59%) | 0.42 |
Depressive Symptoms | 79 (12%) | 75 (27%) | 45 (41%) | <.001 |
Body Mass Index (kg/m2) | 28 ± 5 | 29 ±6 | 28 ± 7 | 0.04 |
Systolic blood pressure (mmHg) | 133 ± 20 | 135 ± 23 | 130 ± 20 | 0.16 |
Diastolic blood pressure (mmHg) | 74 ± 11 | 77 ± 12 | 72 ± 10 | 0.001 |
Total cholesterol (mg/dL) | 176 ± 40 | 182 ± 48 | 175 ± 41 | 0.13 |
HDL cholesterol (mg/dL) | 46 ± 14 | 46 ± 15 | 45 ± 14 | 0.71 |
LV ejection fraction (%) | 62 ± 9 | 62 ± 10 | 61 ± 10 | 0.69 |
LV mass index (g/m2) | 97 ± 25 | 100 ± 30 | 101 ± 26 | 0.11 |
Medications | ||||
Beta-blockers | 352 (56%) | 162 (58%) | 79 (71%) | 0.01 |
ACE-inhibitors or ARBs | 319 (50%) | 139 (50%) | 66 (59%) | 0.19 |
Statins | 421 (67%) | 168 (60%) | 68 (61%) | 0.12 |
Aspirin | 449 (71%) | 206 (74%) | 86 (77%) | 0.34 |
Calcium Channel Blockers | 146 (23%) | 64 (23%) | 37 (33%) | 0.06 |
Nitrates | 116 (18%) | 103 (37%) | 78 (70%) | <.001 |
Seattle Angina Questionnaire, median (IQR) | ||||
Angina Frequency | 100 | 80 (80-90) | 50 (40-60) | <.0 01 |
Quality of Life | 92 (70-100) | 67 (50-75) | 42 (25-58) | <.001 |
Physical Limitation | 86 (67-100) | 67 (50-86) | 50 (33-67) | <.001 |
Abbreviations: ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker; HDL: high-density lipoprotein; IQR: interquartile range; SD: standard deviation.